Rising Incidence and Diagnostic Challenges of Neuroendocrine Cancers

Neuroendocrine cancers (NECs), a rare and often “invisible” group of tumors, are becoming increasingly prevalent in the United Kingdom and worldwide. Despite a significant rise in cases, diagnostic delays and a lack of awareness continue to hinder timely treatment and optimal patient outcomes. This article explores the current state of neuroendocrine cancer, the challenges in diagnosis, and the urgent need for improved awareness and faster diagnostic pathways.

What are Neuroendocrine Cancers?

Neuroendocrine neoplasms (NENs), encompassing neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), develop from cells that combine characteristics of nerve and hormone-producing cells. These cancers can arise in various parts of the body, most commonly in the digestive system, lungs, and pancreas [1]. NETs typically grow slowly, although NECs are more aggressive and fast-growing.

Increasing Incidence Rates

According to Neuroendocrine Cancer UK (NCUK), approximately 6,000 people are diagnosed with neuroendocrine cancers each year in the United Kingdom [1]. Alarmingly, the incidence of these cancers has increased by 371% between 1995 and 2018, significantly higher than the average 118% increase observed for other cancers (excluding non-melanoma skin cancer) [2].

The Diagnostic Odyssey

Despite the rising incidence, diagnosis remains a significant hurdle. On average, it takes four and a half years to receive a diagnosis for neuroendocrine cancer [1]. Nearly half of patients are not diagnosed during their initial consultation, and 16% require ten or more visits to a doctor before receiving a definitive diagnosis. Over half of cases are already at an advanced stage when detected.

Why are Diagnoses Delayed?

The difficulty in diagnosing neuroendocrine cancers stems from several factors. The cancers can develop in diverse locations throughout the body and present with a wide range of non-specific symptoms. These symptoms can include fatigue, pain, skin redness, persistent cough, bloating, flatulence, diarrhea, and unexplained weight loss. Symptoms can also mimic more common conditions, leading to misdiagnosis as asthma, irritable bowel syndrome, or menopause [3].

Living with Neuroendocrine Cancer

Unlike some other cancers where the goal is remission, neuroendocrine cancers often require long-term management. Patients frequently live with the disease for many years, necessitating ongoing care and support. Diagnostic delays not only cause patient distress but also allow the disease to progress, potentially limiting treatment options and worsening outcomes.

The Need for Increased Awareness and Faster Diagnosis

Lisa Walker, Director General of NCUK, emphasizes that neuroendocrine cancers behave and appear differently than more well-known cancers. Accelerating diagnosis is crucial, particularly given the increasing number of cases. Early detection and prompt treatment are essential for improving patient outcomes and quality of life.

Support and Resources

Neuroendocrine Cancer UK provides vital support, information, and resources for individuals and families affected by neuroendocrine cancer. Their helpline is available at 0800 434 6476 [1]. Additional support is available through GPs, specialist teams, and crisis services like SHOUT (85258) and the Samaritans (116 123) [1].